In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment ...

A common terminal pathway is shared by the above three complement pathways: Under the action of C5 convertase, C5 can be bifurcated into C5a and C5b. C5a, the strongest factor, appears in the ...

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent ...

“INF904 is a promising addition to our pipeline of candidates controlling the terminal complement C5a / C5aR pathway. As an orally administered compound, we plan to study if INF904 is especially ...

When complement gets activated, it releases anaphylatoxins C3a and C5a that are potent chemotactic agents. They recruit leukocytes into lesions and also activate cells that express C3a and C5a ...

The cleavage of C5 into fragments C5a and C5b is a critical event during the complement cascade, as C5a is a potent pro-inflammatory anaphylatoxin capable of inducing cell migration, adhesion and ...

develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression ...

InflaRx will participate in a panel - Advances in Dermatology: AD and CSU – being held 10:45-11:20 AM ET, as well as participate in one-on-one investor meetings. Leerink Partners Therapeutics Forum: I ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense ...